Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

Description

The purpose of the study is to examine the feasibility and acceptability of an exercise and nutrition "prehabilitation" program for patients preparing for pancreatic cancer resection (removal).

Conditions

Pancreatic Cancer

Study Overview

Study Details

Study overview

The purpose of the study is to examine the feasibility and acceptability of an exercise and nutrition "prehabilitation" program for patients preparing for pancreatic cancer resection (removal).

Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

Condition
Pancreatic Cancer
Intervention / Treatment

-

Contacts and Locations

Tampa

Moffitt Cancer Center, Tampa, Florida, United States, 33612

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 18 years or older
  • * Biopsy-proven pancreatic ductal adenocarcinoma (PDAC), borderline resectable at diagnosis
  • * Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • * Undergoing neoadjuvant chemotherapy with treatment plan including chemoradiation therapy and surgical resection
  • * Ability to read and speak English
  • * Regular engagement in RT (2x/week targeting all major muscle groups)
  • * Screen failure for exercise safety based on PAR-Q
  • * Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease
  • * Recent fracture or acute musculoskeletal injury that precludes ability to participate in RT
  • * Numeric pain rating scale greater than or equal to a 7 out of 10
  • * Myopathic or rheumatologic disease that impacts physical function

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

H. Lee Moffitt Cancer Center and Research Institute,

Nathan Parker, PhD, PRINCIPAL_INVESTIGATOR, Moffitt Cancer Center

Pamela Hodul, MD, PRINCIPAL_INVESTIGATOR, Moffitt Cancer Center

Study Record Dates

2026-02